Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longboard Pharmaceuticals, Inc. (LBPH : NSDQ)

• Company Description    Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel, transformative medicines for neurological diseases. Longboard Pharmaceuticals Inc. is based in SAN DIEGO. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $4.37 Daily Weekly Monthly 20 Day Moving Average: 4,698 shares Shares Outstanding: 13.59 (millions) Market Capitalization: $59.37 (millions) Beta: -0.32 52 Week High: $11.36 52 Week Low: $3.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.61% 4.05% 12 Week -5.21% 4.21% Year To Date -10.45% 10.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4275 EXECUTIVE SQUARE SUITE 950 - LA JOLLA,CA 92037 USA ph: 619-592-9775 fax: - None http://www.longboardpharma.com

• General Corporate Information    Officers Kevin R. Lind - Chief Executive Officer and President Brandi L. Roberts - Chief Financial Officer Vincent E. Aurentz - Director Corinne Le Goff - Director Casey C. Lynch - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54300N103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 13.59 Most Recent Split Date: (:1) Beta: -0.32 Market Capitalization: $59.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -7.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -29.74 12/31/21 - -24.60 09/30/21 - -33.68 ROA 03/31/22 - -28.41 12/31/21 - -23.69 09/30/21 - -27.98 Current Ratio 03/31/22 - 14.98 12/31/21 - 19.91 09/30/21 - 28.67 Quick Ratio 03/31/22 - - 12/31/21 - 19.91 09/30/21 - 28.67 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.91 12/31/21 - 7.61 09/30/21 - 8.22 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©